Hemab Therapeutics Holdings, Inc. (COAG)

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing treatments for rare and underserved bleeding and blood clotting disorders. Founded in 2020, the company has operations in Denmark and the United States and is headquartered in Cambridge, Massachusetts.

Its lead candidate, HMB-001, is a bispecific antibody designed to restore normal platelet function and is being studied as a preventive treatment for Glanzmann thrombasthenia and Factor VII deficiency. Its second program, HMB-002, is an antibody being developed as a subcutaneous preventive therapy for von Willebrand disease. The company also has additional earlier-stage programs in research. Its common stock trades on Nasdaq under the ticker COAG.